Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives


The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.

The history of diabetes management is one characterized by tremendous advances that have transformed care and life expectancies of patients dating back to the discovery of insulin more than 100 years ago.

Since 1921, the diabetes care team has been the beneficiary of a multitude of other noteworthy advancements, with many of the most recent coming as a result of heightened technology finding a role in management. If there were any drawbacks to the rapid rate of advancement in diabetes technology in the last 20 years, it would be the difficulty in keeping up with the sheer amount of data related to these newer technologies.

With this in mind, Endocrinology Network is proud to introduce its latest multimedia offering, “Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives”. Hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, the monthly podcast is aimed at providing listeners with insight from their real-world experiences on how to best leverage advances in therapeutics and technology to improve diabetes management.

In the first episode, Isaacs and Bellini offer guests insight into their backgrounds and expertise as well as recap recent regulatory news from the first 3 months of 2022 impacting diabetes specialists, including the Eversense 180-day CGM, Dexcom G7’s CE Mark in Europe, and more.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify.

Related Videos
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
© 2024 MJH Life Sciences

All rights reserved.